Thermo Fisher Scientific (TMO)
(Real Time Quote from BATS)
$604.42 USD
+2.32 (0.39%)
Updated Aug 15, 2024 10:04 AM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Brokerage Reports
Thermo Fisher Scientific Inc. [TMO]
Reports for Purchase
Showing records 401 - 420 ( 550 total )
Company: Thermo Fisher Scientific Inc.
Industry: Medical - Instruments
Company: Thermo Fisher Scientific Inc.
Industry: Medical - Instruments
We are terminating coverage of the companies
Provider: KEYBANC CAPITAL MARKETS
Company: Thermo Fisher Scientific Inc.
Industry: Medical - Instruments
Company: Thermo Fisher Scientific Inc.
Industry: Medical - Instruments
Company: Thermo Fisher Scientific Inc.
Industry: Medical - Instruments
Company: Thermo Fisher Scientific Inc.
Industry: Medical - Instruments
Confident in 2018 PTHN Accretion; Increasing PT to $189 from $183
Provider: KEYBANC CAPITAL MARKETS
Company: Thermo Fisher Scientific Inc.
Industry: Medical - Instruments
An Adjacency, but a Different More Complex Animal
Provider: KEYBANC CAPITAL MARKETS
Company: Thermo Fisher Scientific Inc.
Industry: Medical - Instruments
Company: Thermo Fisher Scientific Inc.
Industry: Medical - Instruments
Setting Itself Up for Another Guidance Raise; Upping Estimates - PT
Provider: KEYBANC CAPITAL MARKETS
Company: Thermo Fisher Scientific Inc.
Industry: Medical - Instruments
Research Summary
Provider: KEYBANC CAPITAL MARKETS
Company: Thermo Fisher Scientific Inc.
Industry: Medical - Instruments
Company: Thermo Fisher Scientific Inc.
Industry: Medical - Instruments
Company: Thermo Fisher Scientific Inc.
Industry: Medical - Instruments
Company: Thermo Fisher Scientific Inc.
Industry: Medical - Instruments
Company: Thermo Fisher Scientific Inc.
Industry: Medical - Instruments
Company: Thermo Fisher Scientific Inc.
Industry: Medical - Instruments
No Real Change in Expectations, Though Sentiment May Have Been Too Low
Provider: KEYBANC CAPITAL MARKETS
Company: Thermo Fisher Scientific Inc.
Industry: Medical - Instruments
Medical Technology: 4Q Preview; No Real Changes to Outlooks; Reducing Estimates Again for FX
Provider: KEYBANC CAPITAL MARKETS